Newlink Genetics Cor Now Covered by Analysts at Jefferies Group (NLNK)
Research analysts at Jefferies Group began coverage on shares of Newlink Genetics Cor (NASDAQ: NLNK) in a report released on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
The analysts wrote, “We believe multiple data readouts with potentially positive outcomes over the next 12-18 months offer attractive upside to NLNK shares. Final PIII IMPRESS trial data from algenpantucel-L in surgically resected pancreatic patients should be available in 2H ’14 with two potential interims available in the next 6-12 mo. We estimate 70% odds of the IMPRESS trial with pot’l risk-adjusted sales in pancreatic cancer of $497M in 2023.”
Shares of Newlink Genetics Cor (NASDAQ: NLNK) opened at 19.86 on Thursday. Newlink Genetics Cor has a one year low of $10.40 and a one year high of $18.00. The stock’s 50-day moving average is currently $12.05. The company’s market cap is $508.5 million.
Newlink Genetics Cor (NASDAQ: NLNK) last issued its quarterly earnings data on Monday, May 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.05. The company had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.41 million. Analysts expect that Newlink Genetics Cor will post $-1.37 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at MLV Capital raised their price target on shares of Newlink Genetics Cor from $18.50 to $24.00 in a research note to investors on Tuesday, June 4th. They now have a “buy” rating on the stock. Separately, analysts at Cantor Fitzgerald raised their price target on shares of Newlink Genetics Cor from $18.00 to $25.00 in a research note to investors on Wednesday, May 29th. They now have a “buy” rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Newlink Genetics Cor from $21.00 to $25.00 in a research note to investors on Tuesday, May 7th. They now have a “buy” rating on the stock.
Five equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $23.50.
NewLink Genetics Corporation (NASDAQ: NLNK) is a development-stage company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.